|Awarded On||February 16, 2022|
|Title||Overcoming the CPS1-driven Metabolic Reprogramming and Therapy Resistance in Lethal Prostate Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Ping Mu|
The most lethal type of prostate cancer is called metastatic castration resistant prostate cancer, with a 5-year survival rate of only 28%. One of the biggest challenges in managing this disease is that many patients will inevitably develop resistance to the current "standard-of-care" Androgen Receptor (AR) targeted therapies within 2 years. Therefore, there is an overwhelming need to understand the biology of resistance, develop new measurable biological markers to predict resistance, and create a new therapeutic approach to fight against resistance.
We have found, through a technology called "library screening", that the loss of a gene called IWS1, is a key factor leading to therapy resist...